AJMC ®: How has treatment of complement-driven diseases changed since 2007, when the first complement inhibitor, eculizumab, was approved? SMITH: The development of eculizumab followed our ...
The lectin pathway is the third pathway in the complement cascade, discovered after the classical and alternative pathways. It more closely resembles the classical pathway due to similar binding ...
It was called ‘complement’ because it aided the antibacterial activity of antibodies. However, it is now known that the complement system can be activated early in an infection without the presence of ...
Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...
Current treatment methods for C3 glomerulopathy (C3G) help support kidney function and suppress immune system activity. Emerging therapies interrupt the proteins responsible for disease activity. C3G ...
CAMBRIDGE, Mass., Dec. 10, 2024 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced ...
Image of blood cells. KP104 is a bifunctional, first-in-class biologic that works by selectively inhibiting the alternative and terminal pathways in the complement system. The Food and Drug ...
RESEARCH TRIANGLE PARK, N.C., Jan. 09, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. BCRX today announced that initial data from ongoing phase 1 single ascending dose (SAD) and multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results